Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Total Voting Rights

27 Dec 2006 07:01

ReNeuron Group plc27 December 2006 27 December 2006 (ReNeuron Group plc "The Company") Total Voting Rights For the purposes of the transitional provisions of the Financial ServicesAuthority's Disclosure and Transparency Rules, the Company's total issued sharecapital at the date of this notice is £1,185,241. The Company's issued share capital consists of 118,524,100 ordinary shares of 1peach, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 118,524,100. The above figure of 118,524,100 may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, the Company, under theDisclosure and Transparency Rules. For further information contact:ReNeuron Group plcMichael Hunt, CEO Tel: 44 (0)1483 302 560 Financial DynamicsDavid Yates Tel: 44 (0)20 7831 3113Nicola Daley This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Mar 20207:00 amRNSBlock Listing Review and Total Voting Rights
24th Feb 20207:00 amRNSPositive long-term data in retinal clinical trial
17th Feb 20207:00 amRNSPositive Phase 2a stroke clinical data published
12th Feb 20207:02 amRNSNotification of Major Holdings
12th Feb 20207:01 amRNSNotification of Major Holdings
12th Feb 20207:00 amRNSNotification of Major Holdings
7th Feb 20201:15 pmRNSNotification of Major Holdings
6th Feb 20209:51 amRNSNotification of Major Holdings
2nd Jan 20207:00 amRNSTotal Voting Rights
18th Dec 201912:10 pmRNSNotification of Major Holdings
16th Dec 20193:00 pmRNSNOTIFICATION OF MAJOR HOLDINGS
6th Dec 20197:00 amRNSInterim Results
18th Nov 20197:00 amRNSNotification of Interim Results
23rd Oct 20197:00 amRNSReNeuron's lead cell line shows further potential
17th Oct 20195:36 pmRNSNotification of Major Holdings
17th Oct 20193:21 pmRNSNotification of Major Holdings
14th Oct 20197:00 amRNSPositive clinical data presented at AAO meeting
2nd Oct 20194:40 pmRNSSecond Price Monitoring Extn
2nd Oct 20194:35 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSClinical Update and Conference Presentations
12th Sep 201911:21 amRNSResult of AGM
10th Sep 20197:00 amRNSAGM Trading Update
2nd Sep 20197:00 amRNSBlock Listing Review and TVR
21st Aug 20197:00 amRNSAppointments to Scientific Advisory Board
14th Aug 20197:00 amRNSGrant-funded collaboration with exosome platform
2nd Aug 20194:00 pmRNSPosting of Annual Report and Notice of AGM
2nd Aug 20191:12 pmRNSNotification of Major Holdings
1st Aug 201911:50 amRNSTotal Voting Rights
17th Jul 20197:00 amRNSDirector/PDMR Interest in Shares & Share Options
16th Jul 20197:00 amRNSKey patent grants expand exosome IP portfolio
12th Jul 20197:00 amRNSSenior business development appointment
11th Jul 20197:00 amRNSPreliminary Results
8th Jul 20194:30 pmRNSNotification of Major Holdings
1st Jul 201911:00 amRNSPrice Monitoring Extension
1st Jul 20197:00 amRNSTotal Voting Rights
18th Jun 20194:01 pmRNSNotification of Major Holdings
18th Jun 20197:00 amRNSWebcast of Preliminary Results
14th Jun 201911:09 amRNSReNeuron wins Breakthrough of the Year Award
3rd Jun 20197:00 amRNSTotal Voting Rights
31st May 20197:00 amRNSJefferies 2019 Global Healthcare Conference
9th May 20195:05 pmRNSExercise of options, PDMR dealing and TVR
8th May 20197:00 amRNSYear-end update and results notification
2nd May 20193:43 pmRNSTotal Voting Rights
26th Apr 20194:40 pmRNSSecond Price Monitoring Extn
26th Apr 20194:35 pmRNSPrice Monitoring Extension
26th Apr 20197:00 amRNSClinical update and conference presentation
18th Apr 20193:40 pmRNSShare Purchases by Directors
12th Apr 20192:36 pmRNSExercise of Share Options and TVR
11th Apr 20194:31 pmRNSShare Purchases by Directors
10th Apr 20192:37 pmRNSDirector/PDMR Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.